Supernus Pharmaceuticals Inc. Common Stock (SUPN)
Stock · NASDAQ · Health Care
$37.88as of 10/16/2026
Price chart
Active signals
SUPN Signal Track Record
How signals performed across all stocks →What SUPN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +0.3% | 52% | October 5, 2026 |
| Bollinger Band Breakout | 25 | +0.9% | 56% | June 26, 2026 |
| Bollinger Band BreakdownActive now | 17 | -0.1% | 47% | July 31, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -1.7% | 41% | August 18, 2026 |
| Any 20-session window (baseline) | +0.9% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (P…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 778
- Website
- www.supernus.com
Fundamentals
- 1-day range
- $37.54$39.49
- Market cap
- $2.72B
- P/E (trailing)
- —
- P/E (forward)
- 8.80
- EPS (trailing)
- $-1.91
- Dividend yield
- —
- Beta
- 0.53
- Avg. volume
- 777.0K
How Supernus Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Supernus Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SUPNSupernus Pharmaceuticals Inc. Common Stock$37.88▼ 4.27%Market cap $2.72BP/E —$39.36$59.68
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
- NRIXNurix Therapeutics Inc. Common stock$24.42▼ 2.12%Market cap $2.62BP/E 9.25$9.14$28.23
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- IMNMImmunome Inc. Common Stock$16.47▼ 5.34%Market cap $2.92BP/E —$13.54$30.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.72B | — | $37.88 | ▼ 4.27% | $39.36$59.68 |
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
| NRIX Nurix Therapeutics Inc. Common stock | $2.62B | 9.25 | $24.42 | ▼ 2.12% | $9.14$28.23 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| IMNM Immunome Inc. Common Stock | $2.92B | — | $16.47 | ▼ 5.34% | $13.54$30.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 1 Healthcare Stock Worth Your Attention and 2 We Turn DownYahoo · 10/9/2026
- 1 Unprofitable Stock with Impressive Fundamentals and 2 We AvoidYahoo · 9/30/2026
- Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?Yahoo · 9/28/2026
- 2 Growth Stocks to Add to Your Roster and 1 We QuestionYahoo · 9/28/2026
- Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate UpdateYahoo · 9/28/2026
- Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from IndiviorYahoo · 9/25/2026
- 3 Reasons SUPN is Risky and 1 Stock to Buy InsteadYahoo · 9/21/2026
- Why Did Supernus Pharmaceuticals (SUPN) Move Today?Yahoo · 9/19/2026
Insider Activity
Insider Actions →- Frank Mottola · August 12, 2026 · Tax Withholding797 @ $46.57
- Jack A. Khattar · August 12, 2026 · Option Exercise29.8K
- Jack A. Khattar · August 12, 2026 · Tax Withholding12.6K @ $46.57
- Jonathan Rubin · August 12, 2026 · Option Exercise750
- Jonathan Rubin · August 12, 2026 · Tax Withholding363 @ $46.57
- Padmanabh P. Bhatt · August 12, 2026 · Tax Withholding1.2K @ $46.57
- Timothy C. Dec · August 12, 2026 · Option Exercise1.3K
- Timothy C. Dec · August 12, 2026 · Tax Withholding604 @ $46.57
- Frank Mottola · August 12, 2026 · Option Exercise1.6K
- Padmanabh P. Bhatt · August 12, 2026 · Option Exercise2.5K
- Jonathan Rubin · July 29, 2026 · Grant750
- Frank Mottola · July 29, 2026 · Grant1.6K
- Jack A. Khattar · July 29, 2026 · Grant29.8K
- Padmanabh P. Bhatt · July 29, 2026 · Grant2.5K
- Timothy C. Dec · July 29, 2026 · Grant1.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 54.23M
- Total value held
- $2.69B
- Institutional holders
- 319
- Unknown8.80M
- Unknown3.32M
- Unknown2.47M
- Unknown2.31M
- Unknown2.29M
- Unknown2.04M
- Unknown1.90M
- Unknown1.71M
- Unknown1.62M
- Unknown1.53M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Supernus mentioned in healthcare stock screening article
Supernus Pharmaceuticals was included in a recent Yahoo Finance article discussing healthcare stocks. The piece highlights specific names for investor attention while noting others to avoid, providing context for the company's current market visibility. This media coverage adds to the narrative surrounding the stock without introducing new fundamental data.
Supernus mentioned in healthcare stock screening article. Supernus Pharmaceuticals was included in a recent Yahoo Finance article discussing healthcare stocks. The piece highlights specific names for investor attention while noting others to avoid, providing context for the company's current market visibility. This media coverage adds to the narrative surrounding the stock without introducing new fundamental data.